BI 3034701_Dosage, benefits & legal status
Also known as BI3034701, BI-3034701
The drug that shows 'triple agonist' is a shape, not a mechanism.
Common vial size is what vendors typically sell, not a recommendation. Enter your own vial in the calculator.
What is BI 3034701?
Plain language first. The technical label stays, but it never stands alone.Overview
Readers often treat 'triple agonist' as one thing. It is not. Retatrutide and UBT251 add the glucagon receptor, a target that burns more energy and stirs up the liver. Mazdutide, often lumped in with them, reaches glucagon with GLP-1 alone and is a dual agonist rather than a triple. This one adds NPY2 instead, the receptor the gut hormone peptide YY uses to cut appetite. A 344-person dose-finding trial began in June 2026 and reads out in 2027. Nothing about how much weight it takes off has been published.
BI 3034701 is a peptide agonist at the GLP-1, GIP and NPY2 receptors, originated by Gubra and developed by Boehringer Ingelheim. Where retatrutide's third target is the glucagon receptor, this one's is NPY2, a receptor for peptide YY that sits on appetite circuits. Its sequence, residue count and receptor potencies have not been disclosed.
What it's used for
Nothing yet. It is an investigational long-acting injection for obesity and overweight, in a phase 2 dose-finding trial only.
How does BI 3034701 work?
What it does in the body, and where.Three receptors, and the third one is the whole point. GLP-1 and GIP are the incretin pair behind tirzepatide. What gets added on top is what separates one triple agonist from another.
- 01What the glucagon receptor does, and why this skips itRetatrutide and UBT251 add the glucagon receptor on top of GLP-1 and GIP, raising energy expenditure and pushing the liver to release fuel. That is powerful and it has to be balanced against the two receptors that lower blood sugar. BI 3034701 leaves glucagon out.
- 02NPY2 insteadNPY2 is a receptor for peptide YY, a hormone the gut releases after eating. Activating it reduces appetite through a route separate from GLP-1. So this molecule stacks two appetite brakes and one insulin effect, rather than adding a metabolic accelerator.
- 03What is not knownBoehringer calls the NPY2 contribution a potentially differentiated mechanism still being investigated. That is an honest way of saying nobody has shown yet what it adds in people. No receptor potency figures and no sequence have been released, and the only weight-loss readout anywhere is Gubra's unquantified description of phase 1.
What else is it used for?
Each group carries its own evidence level.Approved means regulators have cleared it for that purpose. Investigational means it is in trials. Early research means it is being studied and is not established.
What the trials are, and are not
Investigational- Human trialThe phase 1 study ran 125 people from June 2024 to October 2025. Its only primary endpoint was drug-related adverse events, but Part B dosed people with overweight or obesity, and Gubra later described the study as showing encouraging weight loss without giving a number.
- Human trialPart A enrolled healthy male volunteers only. Women appear in Part B, among volunteers with obesity or overweight.
- Human trialThe phase 2 study closed recruitment at 344 people across six dose groups and a placebo group, and runs 42 weeks with percentage body weight change as its endpoint.
- No dataIt reads out no earlier than mid-2027. Until then there is no number for how much weight this drug takes off.
How it differs from the triple agonists already here
Research only- No dataRetatrutide and UBT251 are both GLP-1, GIP and glucagon. This is GLP-1, GIP and NPY2. The first two targets match; the third does not. Mazdutide also gets called a triple agonist in casual writing, and it is an oxyntomodulin analog acting at GLP-1 and glucagon only, with no GIP activity at all.
- No dataNPY2 responds to peptide YY, a gut hormone that suppresses appetite. Adding it is a second appetite mechanism rather than the energy-expenditure effect glucagon brings.
- No dataNo receptor potency values, no sequence and no residue count have been released, so the balance between the three cannot be compared with retatrutide's.
The impressive weight-loss figures in Boehringer's July 2026 announcement belong to survodutide, a separate GLP-1 and glucagon drug, not to BI 3034701. No efficacy number of any kind has been published for BI 3034701, although Gubra has described phase 1 as showing encouraging weight loss. It is also not a retatrutide equivalent: both are called triple agonists and they share only two of their three receptors. Phase 1 had adverse events as its single endpoint, so any weight-loss impression of this drug rests on secondary measures the companies have never quantified.
The published record
Papers and trials about BI 3034701
6 papers tagged human · 0 not reviews or lab · 0 clinical trial publications
6 registered trials · none with posted results
Furthest stage reached: Phase 2, under way
Counted from Europe PMC indexing, not read by a person; a human tag can land on reviews, commentary or lab papers; clinical trial publications is the narrower count.
At a glance
Four things to know about BI 3034701
Evidence
Investigational
Category
Weight loss and metabolic
Common vial
Varies
Half-life
Not published
How much, and do you cycle it?
The range, and whether you take breaks.No human dose disclosed; six dose groups are being tested, not disclosed. No established pattern No range
The dosing interval has not been disclosed. The phase 2 trial runs 42 weeks across six dose groups and the registry does not state how often injections are given.
Not publishedNo figure
The phase 1 study measured pharmacokinetics, and nothing from it has been published. Gubra calls the peptide long-acting. No dosing interval has been disclosed, and none can be inferred from the length of the phase 2 trial.
You can compare this against the whole library to see where it sits.
How do I dose and price it?
Enter your vial and your dose. Pick a mix. We show the draw and the cost.The vial holds a fixed amount of drug. Adding more water does not make more drug, it just spreads it thinner, so you draw a bigger number on the syringe for the same dose.
Choose your mix
Measuring the water1 mL = one full 100-unit syringe.
How do you store it?
Before mixing, and after.Nothing to store: it is not sold anywhere.
BI 3034701 has never been marketed, so there is no vial, pen or bottle to keep at home. Supplies for a trial are made, stored and dispensed by the sponsor and the trial pharmacy under conditions set in the protocol. Anything offered for sale under this name did not come from that supply chain.
What are the side effects and cautions?
Known cautions and warnings for this compound.Who should avoid it
- Any use outside the trial: no product exists and no dose has been disclosed
- Anything sold under this name: the sequence has never been published, so a vial cannot be checked against a reference
- Treating it as interchangeable with retatrutide: the third receptor is different
Stop and get help
- Not applicable outside the trial
Common effects
- No numbers from the phase 1 human data have been published
- Nausea, vomiting and diarrhea are the usual effects of drugs hitting GLP-1 and GIP; that has not been measured for this one
Where this page says nothing is established, that means nobody has studied it, not that a compound is safe.
Is BI 3034701 approved?
And where the numbers on this page come from.No. BI 3034701 is not approved anywhere and is currently in company-run clinical trials. There is no legal route to obtain it outside a trial.
- Approval statusInvestigational
- RouteUnder the skin (subcutaneous)
- Checked24 October 2026
- DoseNo dose has been established in people.
- Vial sizeFrom what vendors typically list; not a recommendation.
- SourcesGubra regulatory release, Boehringer advances the triple-agonist peptide into mid-stage development, December 8, 2025Gubra, Boehringer Ingelheim advances the triple agonist peptide into phase 2, April 28, 2026Boehringer Ingelheim, BI 3034701 enters phase 2 development, July 16, 2026Phase 1 trial record, ClinicalTrials.gov NCT06352437Phase 2 trial record, ClinicalTrials.gov NCT07662122
What has happened recently
Not approved anywhere, and no efficacy figure has been published. The phase 1 study (NCT06352437) completed on October 7, 2025 with 125 participants, and its only primary endpoint was the occurrence of drug-related adverse events. It still measured weight: Gubra reported on December 8, 2025 that the study showed a favorable safety and tolerability profile and encouraging weight loss, and that Boehringer was taking the peptide into mid-stage development. No number accompanied that description, then or since. The phase 2 study (NCT07662122) is a 42-week dose-finding trial with 344 participants across six dose groups and one placebo group, started June 30, 2026 and now closed to recruitment, with a primary completion date of June 26, 2027 and percentage change in body weight at week 42 as its endpoint. Gubra announced on April 28, 2026 that Boehringer planned to start phase 2 in mid-2026; the trial began on June 30 and Boehringer announced it on July 16. There is no FDA substance record and no International Nonproprietary Name.
You can compare this against the whole library, or read how to check a seller.
What else is like BI 3034701?
Others in GLP-1 agonists, side by side.If you're weighing BI 3034701, it's worth reading Bofanglutide (GZR18), CT-388, and Danuglipron in the same class.
The drug that shows 'triple agonist' is a shape, not a mechanism.
- Dose
- No human dose disclosed; six dose groups are being tested
- How often
- Not disclosed
Semaglutide with two small changes, tested as an injection every two weeks. Its China phase 3 met its main goal in 2026, the company reports; in a US phase 2 it trailed tirzepatide.
- Dose
- 24 or 48 mg every two weeks, after a step-up from 3 mg (phase 3 trials)
- How often
- Every two weeks
An experimental weekly weight-loss shot in the tirzepatide family.
- Dose
- 4 up to 24 mg per week (trial doses)
- How often
- Weekly
An experimental weight-loss pill whose development was stopped over a liver-injury signal.
- Dose
- 40 up to 200 mg per dose
- How often
- Daily
Guides for this compound
- How to Reconstitute a Peptide
Mix peptide powder with bacteriostatic water, step by step.
- How to Read an Insulin Syringe
Read the units, convert to millilitres, and draw the exact dose.
- mcg vs mg: The Peptide Dosing Mistake to Avoid
Your vial says mg and your protocol says mcg. Here is the conversion and how to check it.
- How to Read a Peptide COA
What the purity number does and does not tell you, and how to spot an edited report.
- How to Vet a Peptide Vendor
Independent COAs, HPLC purity, and the red flags that mean walk away.
Sources
- Gubra regulatory release, Boehringer advances the triple-agonist peptide into mid-stage development, December 8, 2025(2025)The only phase 1 readout ever released. Describes a randomized, placebo-controlled study in healthy volunteers and people with overweight or obesity that showed a favorable safety and tolerability profile and encouraging weight loss, headlined as encouraging weight-loss signals. Calls the peptide long-acting and first-in-class. No figure of any kind is given, the receptors are not named, and no phase 2 detail or milestone amount appears.
- Gubra, Boehringer Ingelheim advances the triple agonist peptide into phase 2, April 28, 2026(2026)Calls BI 3034701 an investigational, potential first-in-class triple GLP-1, GIP and NPY2 receptor agonist peptide, and states that Boehringer Ingelheim is responsible for global clinical development and commercialization. No preclinical or phase 1 figures are given.
- Boehringer Ingelheim, BI 3034701 enters phase 2 development, July 16, 2026(2026)Describes a potential first-in-class GLP-1/GIP/NPY receptor agonist addressing obesity through three pathways, with NPY2 called a potentially differentiated mechanism still being investigated. Phase 1 is summarized as a generally favorable safety and tolerability profile with no numbers. The weight-loss percentages in this release belong to survodutide, a different drug.
- Phase 1 trial record, ClinicalTrials.gov NCT06352437(2025)Completed phase 1, 125 participants actual, June 10, 2024 to October 7, 2025. Single subcutaneous doses in healthy male volunteers in Part A, multiple rising subcutaneous doses in volunteers with obesity or overweight in Part B. The sole primary outcome is the occurrence of any drug-related treatment-emergent adverse event.
- Phase 2 trial record, ClinicalTrials.gov NCT07662122(2026)A phase 2, randomized, double-blind, parallel-group, 42-week dose-finding trial. Active, not recruiting, with 344 participants actual. Started June 30, 2026, primary completion estimated June 26, 2027. Seven arms: six BI 3034701 dose groups and one placebo. Primary outcome is percentage change in body weight from baseline at week 42.
Beyond these, 6 records are indexed. Browse the records